GSK shares fell more than 5% after U.S. health officials narrowed their recommendation of respiratory syncytial virus vaccines to a smaller age range and more at-risk patients.
GSK Slumps After CDC Narrows Age Recommendation for RSV Shots
Editor Picks
Must read
Popular this week
National
Copyrights 2020 CBNC.com - All rights reserved